Rothblatt's UTHR May Exercise-and-Sell: $13M at 4x Strike

Martine Rothblatt, Chairperson and CEO of United Therapeutics, filed a 30-transaction Form 4 sequence on May 11, 2026 that combined three option exercises with twenty-seven open-market sales. The mechanics are clean: 9,500 options exercised at a strike of $146.03, immediately offset against twenty-seven sales clustered between $574.38 and $580.44 per share. Total proceeds across the May window come to approximately $13.4 million. Latest filing accession on record is 0001106578-26-000051.

The transaction codes matter here. The 'M' tickets are option exercises, not market trades — they convert vested compensation into common stock at a pre-set strike. The 'S' tickets are the open-market sales that follow. Combined, this is the canonical exercise-and-sell structure used to fund the tax bill on a vested option grant. It is not a directional view on UTHR's pulmonary-arterial-hypertension franchise, and framing it as a CEO selling on conviction would be inaccurate.

The economics of the May 11 print

At a strike of $146 and a market clear above $574, each option converted on May 11 carried more than $428 of intrinsic value before tax. The 9,500-option exercise alone produced roughly $4.07 million of taxable spread. Selling 27 lots into the $574-580 range — totaling proceeds near $13.4 million — covered the tax obligation, the strike cost, and produced residual after-tax cash. Common Class A shares remaining on the Form 4 Table I after the final sale: 15,288.

Rothblatt's career sells per our insider profile total $1.05 billion against $15.1 million in lifetime buys across 6,600 transactions — a pattern consistent with multi-year option-grant cycles for a long-tenured biotech CEO. The May 2026 window fits that pattern.

What the institutional roster says

UTHR carries 878 reported institutional holders. The top six positions are weighted toward both passive index complexes and biotech-specialist active funds:

• BlackRock, Inc. — $2.52 billion
• Avoro Capital Advisors — $1.27 billion
• Wellington Management Group — $1.19 billion
• Vanguard Portfolio Management — $1.19 billion
• Vanguard Capital Management — $1.16 billion
• Renaissance Technologies — $930 million

The mix matters for interpreting the May filing. BlackRock and the two Vanguard subsidiaries are mandated index exposure. Wellington and Avoro Capital Advisors — a healthcare-focused hedge fund — are the active mandates whose 13F next quarter will register any reaction. Renaissance is a quantitative book; its position size reflects model output, not a fundamental view.

13D/G context: no controlling holder

UTHR's Schedule 13G register confirms the institutional picture rather than overriding it. The two most recent >5% filings are:

• Vanguard Capital Management LLC — 5.190% / 2,278,348 shares (SC 13G, April 30, 2026).
• Wellington Management Group LLP — 5.700% / 2,441,492 shares (Schedule 13G, February 10, 2026).

No insider or activist appears in the >5% beneficial ownership register. Rothblatt's personal Form 4 position — 15,288 directly-held Class A shares after the May 11 sales — is consistent with a CEO whose compensation is paid in periodic option grants, not in accumulated common stock. This is structurally different from founder-controlled biotech where Schedule 13D filings dominate the ownership story.

What the May filing does not say

Three editorial guard-rails apply to a clean exercise-and-sell sequence like this one:

1. The CEO did not 'dump' stock. Twenty-seven sales executed against an option exercise on the same trading day is the textbook mechanical pattern for taxable-event funding, not a bearish posture.
2. The 15,288 Class A shares 'remaining' on the Form 4 do not represent the CEO's full economic interest in UTHR. Unvested option awards, RSU pools, and any deferred compensation programs are not surfaced on Form 4 Table I.
3. The transactions carry no 10b5-1 plan footnote in the Form 4 fields visible to our database. That does not mean a plan is absent — it means we cannot confirm one. Discretionary framing therefore requires external corroboration; we have none.

Watch the next 90 days

Three anchors define the next observable window:

1. Next UTHR earnings release. The earnings tape is the next valuation reference for the May 11 sales window.
2. Avoro Capital Advisors' next 13F. The healthcare-specialist position will be the cleanest active-mandate read on whether the May tape changed institutional view.
3. Any new Schedule 13G/A on UTHR. The April 30, 2026 Vanguard Capital Management filing is the freshest reference; an amendment crossing the 6% threshold from BlackRock or Wellington would shift the institutional concentration narrative.

For the full Rothblatt insider history and additional cross-quarter context, follow the profile page. Aggregate signal context lives on the insights feed.

FAQ

Why did Martine Rothblatt sell UTHR stock in May 2026?

The May 11, 2026 sales were paired with three option exercises at a $146 strike on the same day. The structure is the canonical exercise-and-sell pattern used to fund the tax bill on vested compensation — not a discretionary directional bet on United Therapeutics.

How much UTHR stock does Rothblatt own?

After the May 11, 2026 sales, the Form 4 reports 15,288 Class A shares directly held. The figure excludes unvested options, RSU pools, and deferred compensation that do not appear on Form 4 Table I.

What was the strike price on the May 2026 option exercise?

$146.03 per share against open-market sales clearing between $574 and $580 — a roughly 4x intrinsic-value print at the time of exercise, per Form 4 accession 0001106578-26-000051.